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periostin expression in fibroblasts via
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Periostin is a multifunctional extracellular matrix pro-
tein involved in various inflammatory diseases and
tumor metastasis; however, evidence regarding
whether and how periostin actively contributes to
inflammation-associated tumorigenesis remains
elusive. Here, we demonstrate that periostin defi-
ciency significantly inhibits the occurrence of
colorectal cancer in azoxymethane/dextran sulfate
sodium-treated mice and in ApcMin/+ mice. More-
over, periostin deficiency attenuates the severity of
colitis and reduces the proliferation of tumor cells.
Mechanistically, stromal fibroblast-derived periostin
activates FAK-Src kinases through integrin-medi-
ated outside-in signaling, which results in the activa-
tion of YAP/TAZ and, subsequently, IL-6 expression
in tumor cells. Conversely, IL-6 induces periostin
expression in fibroblasts by activating STAT3, which
ultimately facilitates colorectal tumor development.
These findings provide the evidence that periostin
promotes colorectal tumorigenesis, and identify
periostin- and IL-6-mediated tumor-stroma interac-
tion as a promising target for treating colitis-associ-
ated colorectal cancer.INTRODUCTION
Colorectal cancer (CRC) is one of the most common malignant
tumors, with a high incidence and mortality. Previous studies
have demonstrated that genetic mutation of adenomatous
polyposis coli (APC) is closely associated with colorectal
tumorigenesis (Moser et al., 1990; Rakoff-Nahoum and Medzhi-
tov, 2007; Karki et al., 2016). Chronic inflammation is another
recognized driver of CRC (Grivennikov et al., 2010; HuberCell
This is an open access article undet al., 2012). Current evidence has revealed that the interac-
tions between tumor cells and their adjacent stromal cells
play a critical role in colorectal tumorigenesis (Koliaraki et al.,
2012). However, it is still unclear how the resident stromal cells
are activated by their adjacent tumor cells under the inflamma-
tory condition, and how stromal cell-derived cytokines and
extracellular matrix (ECM) proteins educate tumor cells in the
pathogenesis of CRC.
Periostin (encoded by Postn) was originally identified as an
adhesion protein in mouse osteoblastic cells (Takeshita et al.,
1993; Horiuchi et al., 1999). Periostin is rarely detected in
most normal adult tissues, but it is highly induced in lesions,
inflammation, and tumors (Conway et al., 2014; Liu et al.,
2014; Izuhara et al., 2017; Kudo, 2017; Ma et al., 2019). As a
multifunctional ECM protein, periostin contributes to tumor
microenvironment remodeling during tumor progression. During
breast tumor metastasis, cancer-associated fibroblast (CAF)-
derived periostin is involved in the formation of the cancer
stem cell niche, the perivascular niche, and the premetastatic
niche in the lung (Malanchi et al., 2011; Wang and Ouyang,
2012; Ghajar et al., 2013; Wang et al., 2016b). Activated hepatic
stellate cell-derived periostin promotes the formation of a
fibrotic microenvironment to facilitate the liver metastatic
outgrowth of pancreatic cancer cells (Nielsen et al., 2016). Our
previous study demonstrated that periostin promotes the
metastatic outgrowth of colon tumors in the liver by enhancing
cell survival and angiogenesis (Bao et al., 2004). However, it
remains largely unclear whether and how periostin is involved
in colorectal tumorigenesis, especially in the development of
colitis-associated CRC (CAC).
Here, we demonstrate that periostin deficiency suppresses
intestinal tumorigenesis in azoxymethane (AOM)/dextran sulfate
sodium (DSS)-treated mice and ApcMin/+ mice. We further
observe that the deletion of periostin significantly reduces the
proliferative cells and decreases nuclear YAP/TAZ in colorectal
tumors in mice. Our results unveil that CAF-derived periostin
promotes colorectal tumorigenesis through integrin-focal adhe-
sion kinase (FAK)-Src signaling-mediated YAP/TAZ activation.Reports 30, 793–806, January 21, 2020 ª 2019 The Author(s). 793
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
RESULTS
Periostin Deficiency Inhibits Intestinal Tumorigenesis in
AOM/DSS-Treated Mice and ApcMin/+ Mice
To determine the impact of periostin on colorectal tumorigen-
esis, we used AOM/DSS to induce CAC in mice. To this end,
mice received a single injection of AOM followed by three cycles
of DSS administration (Figure S1A). During the course of AOM/
DSS treatment, periostin knockout (Postn/) mice exhibited a
significant reduction in body weight loss in comparison to wild-
type (WT) mice (Figure 1A). During the first cycle of DSS treat-
ment, the disease activity index was significantly decreased
in Postn/ mice compared to WT mice (Figure S1B). Histologi-
cally, AOM/DSS-administrated Postn/ mice displayed clearly
attenuated inflammation severity (Figure 1B). Moreover, the his-
topathological score was greatly reduced in the distal colon of
Postn/ mice compared to that of WT mice (Figure 1C). The
enhanced colitis is invariably accompanied bymore infiltrated in-
flammatory cells in the lamina propria. To further investigate
whether periostin has an effect on immune cell infiltration under
inflammatory conditions, we performed immunohistochemical
assays to analyze the dense infiltration of inflammatory cells in
the distal colon of WT and Postn/ mice during the early and
late stages of AOM/DSS administration. We found fewer infil-
trated inflammatory cells in the colon tissues of Postn/ mice
than in those of WT controls (Figures 1D and 1E), suggesting
that the deletion of periostin retards inflammatory cell infiltration
in the distal colon of AOM/DSS-treated mice. At the end point of
the experimental protocol, the colons of both WT and Postn/
mice were collected and tumors were analyzed. Tumor inci-
dence in WT mice was 100%, whereas <80% of Postn/ mice
formed tumors or polyps in the distal colon. In particular, a signif-
icant decrease in tumor numbers and a remarkable reduction in
tumor size were observed in the colons of Postn/ mice
compared to WT mice (Figures 1F–1I, S1C, and S1D). The
average tumor number per colon in Postn/ mice (2.5 ± 0.4)
was less than in WT mice (5.0 ± 0.4) (Figure 1F). Moreover,
Postn/ mice showed a significant reduction in the average tu-
mor size compared with WT controls (Figure 1H). Although there
was no significant difference in the number of small tumors
(%1mm diameter) betweenWT and Postn/mice, 53.1% of tu-
mors in WTmice developed into large tumors (>2 mm diameter),
while only 37.5% of tumors in Postn/ mice developed into
large tumors (Figure 1I). The number of proliferative cells was
dramatically decreased in the tumors of Postn/ mice
compared to those in WT tumors (Figures 1J–1L). Furthermore,
the mRNA levels of many inflammation-associated cytokines
such as interleukin-6 (IL-6), tumor necrosis factor a (TNF-a),
and IL-1b were significantly reduced in the distal colonic tissues
of Postn/ mice compared with those of WT mice after AOM/
DSS treatment (Figures 1M, S1E, and S1F). We also found that
the protein levels of IL-6, TNF-a, and IL-1b were markedly
decreased in the distal colonic tissues of Postn/ mice (Fig-
ure 1N). Consistent with these results, we observed greatly
decreased levels of inducible nitric oxide synthase (iNOS),
extracellular signal-regulated kinase 1/2 (ERK1/2), and signal
transducer and activator of transcription 3 (STAT3) phosphoryla-
tion in the colon tissue of Postn/ mice compared with WT794 Cell Reports 30, 793–806, January 21, 2020mice at day 80 of AOM/DSS treatment (Figure S1G), indicating
that the absence of periostin prevents the activation of inflamma-
tory signaling pathways in mice. These findings suggest
that periostin deficiency inhibits colitis-associated colorectal
carcinogenesis.
To further investigate whether periostin promotes colorectal
tumorigenesis in a spontaneous mouse intestinal tumor model,
we used ApcMin/+ mice and Postn+/ mice to generate Postn+/+
ApcMin/+ mice and Postn/ApcMin/+mice. After 6 months, tu-
mors in the whole intestinal tract were detected. We found that
Postn/ApcMin/+ mice had a lower tumor burden than Postn+/+
ApcMin/+ mice both in the small and large intestines (Figures
S2A–S2E). In addition, fewer Ki67+ cells were observed in the
small and large intestines of Postn/ApcMin/+ mice compared
with Postn+/+ApcMin/+ mice (Figures S2F and S2G). These find-
ings were similar to the observation obtained from the AOM/
DSS-induced CAC model, suggesting that the absence of peri-
ostin significantly suppresses intestinal tumorigenesis in
different mouse models of colorectal tumors.
Periostin Deficiency Inhibits the Precancerous Lesion
Formation in the Inflamed Colon Tissues of Mice
As periostin has a critical role during the early phases of the
inflammation (Figures 1A–1E, 1M, 1N, and S1B), we reasoned
that pathological change differences between WT and
Postn/ mice may exist during early stages of the CAC pro-
gression. To this end, we examined the expression of periostin
in the inflamed colonic tissue sections of WT mice treated with
AOM/DSS for 15 days. Immunohistochemical staining showed
that a higher level of periostin was deposited in the inflamed
colon tissues compared to the normal colon tissues (Fig-
ure S3A). As shown in Figures S3B and S3C, a significant
decrease in the incidence of dysplasia in Postn/ mice was
observed compared with that in WT mice. In contrast, the num-
ber of goblet cells in the colon of Postn/ mice was greater
than that in WT mice (Figures S3D and S3E), indicating that ge-
netic ablation of periostin may protect secretory epithelial cells
from damage under the inflammatory disorder. Furthermore,
Postn/ mice had fewer proliferative cells in the distal colon
sections than WT mice after the first cycle of AOM/DSS admin-
istration (Figures S3F–S3I). Epithelial barrier dysfunction is
prominent in patients with inflammatory bowel disease and is
always related to the severity of inflammation disorder in ani-
mals (Sharma et al., 2018). After DSS administration, the
epithelial barrier is permeable and tight junction is lost within
2 days (Huber et al., 2012). Thus, we further analyzed the effect
of periostin deficiency on tight junctions during the early stage
(on day 8) of AOM/DSS administration. We found that AOM/
DSS-treated Postn/ mice exhibited a significant increase in
the expression of tight junction markers compared with AOM/
DSS-treated WT mice (Figure S3J). In addition, even at this
early time point, we observed significantly decreased produc-
tion of inflammatory mediator markers and reduced levels of tu-
mor surrogate markers in the distal colon lysates of Postn/
mice compared with WT mice (Figures S3K and S3L). These
results demonstrate that the absence of periostin prevents pre-
cancerous lesion formation in colon tissues during the early
phase of CAC progression.
Figure 1. Periostin Deficiency Attenuates Colitis-Associated Colorectal Tumorigenesis in Mice
(A) Body weight changes in WT (n = 5) and Postn/ (n = 4) mice during the course of AOM/DSS treatment.
(B and C) H&E staining (B) and histopathological score (C) of the distal colon sections of AOM/DSS-treated WT (n = 6) and Postn/ (n = 6) mice. Scale bars,
100 mm.
(D and E) Immunohistochemical staining of CD45, F4/80, andGr-1 (D) and quantification of CD45+, F4/80+, andGr-1+ cells (E) in the inflamed colon sections ofWT
(n = 6) and Postn/ (n = 6) mice. Scale bars, 50 mm.
(F and G) Colon tumors (F) and tumor load (G) of WT (n = 19) and Postn/ (n = 16) mice after AOM/DSS colitis.
(H) The average tumor size in WT (n = 16) and Postn/ (n = 14) mice.
(I) The number of small, medium, and large tumors of WT (n = 19) and Postn/ (n = 16) mice.
(J–L) Immunohistochemical staining of Ki67 and BrdU (J) and quantification of Ki67+ (K) and BrdU+ (L) cells in tumor sections of WT (n = 6) and Postn/ (n = 6)
mice. Scale bars, 50 mm.
(M and N) Relative mRNA (M) and protein (N) levels of the indicated inflammatory mediators (n = 5–6 mice each group).
Each symbol represents one mouse (C, E, F–I, and K–N). In all of the panels, data are the means ± SEMs; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n.s.,
not significant. Two-way ANOVA (A) or Student’s t test (C, E, F–I, and K–N). See also Figures S1, S2, and S3.
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Figure 2. Periostin Is Mainly Derived from Stromal Fibroblasts in Mouse Colorectal Tumors
(A) Periostin expression and deposition in normal and colorectal tumor tissues. Scale bars, 50 mm.
(B–D) Co-staining of periostin with a-SMA (B), vimentin (C), or epithelial cell adhesion molecule (EpCAM) (D) in AOM/DSS-induced tumors. Scale bars, 25 mm.
(E) Body weight changes in BM chimera mice during AOM/DSS treatment (n = 5–10 mice per group). For statistical comparison, the asterisk indicates Postn/
BM > Postn/ versus WT BM > WT; # indicates WT BM > Postn/ versus WT BM > WT.
(F and G) H&E staining (F) and histological score analysis (G) of colon tissue sections of BM chimera mice after AOM/DSS colitis (n = 5–9 mice per group). Scale
bars, 100 mm.
(legend continued on next page)
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Periostin Is Mainly Derived from Stromal Fibroblasts in
Mouse Colorectal Tumors
Next, we determined the cellular source of periostin in colorectal
tumors. We found that the level of periostin was low in normal
colon tissues and its deposition closely surrounded the
pericryptal fibroblasts (Figure 2A). By contrast, a highly elevated
level of periostin was observed both in the AOM/DSS-induced
mouse colorectal tumors and in the Apcmutation-related mouse
tumors (Figures 2A and S4A). Immunohistochemical staining
assays also revealed that periostin was deposited in tumor stro-
mal cells but not in tumor cells (Figure 2A). Immunofluorescence
co-staining assays further determined that a-smooth muscle
actin-positive (a-SMA+) or vimentin+ stromal cells, but not
epithelial-derived tumor cells, contributed to the production of
periostin (Figures 2B–2D), indicating that periostin is mainly
derived from tumor stromal fibroblasts. We also observed an
extremely low amount of periostin deposition in surrounding
macrophages in colitis-associated colorectal tumors (Fig-
ure S4B). To further determine what kinds of stromal cells, stro-
mal fibroblasts, or bone marrow (BM)-derived macrophages
were the dominant source of periostin in colorectal tumorigen-
esis, we performed BM transplantation assays to generate four
groups of BM chimera mice: Postn/ mice transplanted with
BM from WT mice (WT BM > Postn/), WT mice transplanted
with BM from Postn/ mice (Postn/ BM > WT), and the two
control groups consisting of Postn/ mice transplanted with
BM from Postn/ mice (Postn/ BM > Postn/), and WT
mice transplanted with BM from WT mice (WT BM > WT).
Next, we administrated these four groups of BM chimera mice
with AOM/DSS to induce colitis-associated tumor formation.
Postn/ mice receiving BM from WT or Postn/ mice showed
body weight loss at a significant reduction level, compared to
WT mice receiving either BM from Postn/ or WT mice (Fig-
ure 2E). During the early phases of tumor progression, the dis-
ease activity index was significantly lower in Postn/ mice
transplanted with BM from WT or Postn/ mice than in WT
mice transplanted with BM from WT or Postn/ mice (Fig-
ure S4C). Moreover, compared with irradiated WT mice,
Postn/ mice receiving lethal irradiation exhibited significantly
decreased histological scores in the distal colonic tissue sec-
tions after AOM/DSS treatment for 80 days (Figures 2F and
2G), as well as fewer infiltrated inflammatory cells in the irradia-
tion-insensitive compartment of Postn/ mice (Figures 2H and
2I). These data suggest that periostin-deficient mice trans-
planted with BM cells have weakened colitis disease severity af-
ter AOM/DSS colitis. Postn/ mice receiving either WT or
Postn/ mice-derived BM cells developed significantly
decreased tumor numbers and reduced tumor loads than WT
mice receiving Postn/ or WT mice-derived BM cells (Figures
2J, 2K, and S4D–S4F). However, we observed no significant
difference in tumor numbers or tumor load between WT mice
transplanted with either WT mice-derived BM cells or Postn/(H and I) Immunohistochemical staining of CD45, F4/80, and Gr-1 (H) and quant
chimera mice (n = 5–9 mice per group). Scale bars, 50 mm.
(J and K) Tumor number (J) and tumor load (K) in AOM/DSS-treated BM chimera
Each symbol represents onemouse (G and I–K). In all of the panels, data are prese
not significant. Two-way ANOVA (E) or Student’s t test (G and I–K). See also Figmice-derived BM cells, as well as between Postn/mice trans-
planted with either Postn/mice-derived BM cells or WT mice-
derived BM cells (Figures 2J, 2K, and S4D–S4F). Thus, these
results demonstrate that periostin is mainly derived from stromal
fibroblasts during colorectal tumorigenesis.
Periostin Promotes Colorectal Tumor Cell Proliferation
In Vitro
Given that our results (Figures 1J–1L, S2F, and S2G) demon-
strated that periostin deficiency decreases proliferative cells
in the tumors of AOM/DSS-treated mice and ApcMin/+ mice,
we further detected the proliferation-promoting capacity of
periostin in vitro. We treated the CRC cell line CMT93 with
the conditioned medium (CM) of the primary CAFs isolated
from colorectal tumors in WT and Postn/ mice. We observed
that there were fewer Ki67+ or BrdU+ cells in CMT93 cells
treated with Postn/ CAF CM than in WT CAF CM-treated
cells (Figures 3A–3D). Moreover, recombinant mouse periostin
protein (rmPeriostin)-treated CMT93 cells showed many more
proliferative cells than control groups (Figures 3E–3H). MTT as-
says also showed that rmPeriostin-treated CMT93 cells had a
higher proliferative capability than PBS-treated cells (Figure 3I).
These data suggest that periostin promotes the proliferation of
colorectal tumor cells in vitro.
Periostin Induces YAP/TAZ Activation in Colorectal
Tumor Cells
Next, we sought to explore the mechanisms by which periostin
promotes cell proliferation and colorectal tumorigenesis. Previ-
ous studies demonstrate that the transcriptional cofactor YAP
plays a critical role in regulating tissue regeneration and tumor-
igenesis in the intestine (Zhou et al., 2011; Cai et al., 2015; Yui
et al., 2018). Periostin is a well-known extracellular player in
tissue regeneration, inflammation, and tumor progression (Con-
way et al., 2014; Liu et al., 2014). Thus, we determined whether
periostin acts as an extracellular regulator of YAP signaling in
colorectal tumor development. To this end, we determined
the levels of YAP and TAZ in the colon tumor tissues of WT
and Postn/ mice. We found that both the protein and
mRNA levels of YAP and TAZ were greatly decreased in the
tumors of Postn/ mice compared with WT mice (Figures
4A–4C). The deletion of periostin resulted in attenuated YAP/
TAZ nuclear localization in the colorectal tumor cells (Figure 4B),
indicating that periostin deficiency decreases YAP/TAZ activa-
tion during colorectal tumorigenesis. Activated YAP serves as a
transcriptional co-factor of TEADs to induce their target gene
expression. qRT-PCR analysis further revealed that the produc-
tion of their target genes, such as Ankrd1, Ctgf, and Cyr61, was
markedly reduced in the tumor lysates of Postn/ mice relative
to the production in WT tumor lysates (Figure 4C). To further
determine whether periostin induces YAP/TAZ activation in
colorectal tumor cells, we detected nuclear translocation ofification of CD45+, F4/80+, and Gr-1+ cells (I) in inflamed colon sections of BM
mice (n = 5–9 mice per group).
nted asmeans ± SEMs; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n.s.,
ure S4.
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Figure 3. Periostin Promotes Colorectal Tumor Cell Proliferation
(A–D) Representative images of immunofluorescence staining of Ki67 (A) and BrdU (C) and quantification of Ki67+ (B) and BrdU+ (D) cells in CMT93 cells treated
with conditioned medium (CM) of WT or Postn/ CAFs for 24 h (n = 4 biological replicates). Scale bars, 25 mm.
(E–H) Representative images of the immunofluorescence staining of Ki67 (E) and BrdU (G) and quantification of Ki67+ (F) and BrdU+ (H) cells in CMT93 cells
treated with rmPeriostin for 24 h (n = 3 biological replicates). Scale bars, 25 mm.
(I) Analysis of the proliferation ability of CMT93 cells treated with or without rmPeriostin for the indicated time by MTT assay (n = 4 biological replicates).
Each point represents the percentage of Ki67+ (B and F) or BrdU+ (D and H) cells per macroscopic field. Each value represents mean ± SEM; *p < 0.05, **p < 0.01,
****p < 0.0001. Student’s t test. See also Figure S2.YAP/TAZ in CMT93 cells treated with WT and Postn/ CAF
CM, respectively. Notably, Postn/ CAF-CM, but not WT
CAF-CM, failed to enhance YAP/TAZ nuclear translocation in
CMT93 cells (Figures 4D and 4E). These results were further
confirmed by rmPeriostin-induced YAP/TAZ nuclear localiza-
tion in CMT93 cells (Figures 4F and 4G). Moreover, rmPeriostin
treatment strongly elevated the levels of YAP and TAZ in a
time- and dose-dependent manner (Figures 4H and 4I). Admin-
istration of CMT93 cells with rmPeriostin showed a significant
increase in the expression of YAP/TAZ target genes, but this ef-
fect was prevented by knocking down YAP/TAZ with short
interfering RNAs (Figures 4J and S5A). These findings suggest
that periostin enhances YAP/TAZ activation in colorectal tumor
cells in vivo and in vitro.
As a downstream effector of the Hippo signaling pathway,
YAP can be directly phosphorylated by large tumor suppressor
kinases 1 and 2 (LATS1/2) on several residues (Moroishi et al.,
2015; Gregorieff et al., 2015; Hong et al., 2016). Phosphorylation
of YAP at Ser127 is known to enhance YAP cytoplasmic localiza-798 Cell Reports 30, 793–806, January 21, 2020tion and degradation by the proteasome (Guo et al., 2018). Phos-
phorylation-dependent nucleocytoplasmic shuttling of YAP is
tightly associated with its activity (Zhao et al., 2010). We found
that periostin significantly increased the abundance of YAP but
reduced the phosphorylated level of YAP (Figures 4A, 4H, and
4I). Moreover, the treatment of rmPeriostin rescued the nuclear
localization of YAP/TAZ in CMT93 cells grown even at high
confluence (Figure S5B). To determine whether LATS1/2 were
involved in regulating YAP phosphorylation and nuclear localiza-
tion induced by periostin, we adopted short interfering RNAs to
knock down LATS1/2 in CMT93 cells (Figure S5C) and treated
them with rmPeriostin alone or in combination with RGD, an
Arg-Gly-Asp motif peptide for binding and inhibiting integrin re-
ceptors. Notably, RGD treatment significantly prevented perios-
tin-induced YAP/TAZ nuclear translocation, while LATS1/2
knockdown entirely reversed this effect, as evidenced by a highly
increased percentage of YAP/TAZ nuclear localization (Figures
4K and S5D). In line with this, rmPeriostin treatment caused a
significant reduction in LATS1 phosphorylation (Figure S5E).
Figure 4. Periostin Enhances the Activation of YAP/TAZ in Colorectal Tumor Cells
(A) Western blot analysis of YAP, TAZ, CTGF, and p-YAP in the lysates of AOM/DSS-induced colorectal tumors (n = 3 mice each group). The experiments were
repeated three times.
(B) Immunohistochemical staining of YAP/TAZ in the colorectal tumor sections from AOM/DSS-treated WT and Postn/ mice or from Postn+/+ApcMin/+ and
Postn/ApcMin/+ mice. Scale bars, 50 mm.
(C) Relative mRNA levels of YAP, TAZ, and their target genes in colorectal tumors of WT (n = 5) and Postn/ (n = 5) mice.
(D–G) Immunofluorescence staining of YAP/TAZ (D and F) and quantification of nuclear YAP/TAZ (E and G) in CMT93 cells treated with WT or Postn/ CAF-CM
(D and E), or treated with rmPeriostin (F and G) for 24 h (n = 3 biological replicates). Scale bars, 25 mm. Each point represents one macroscopic field.
(H and I) Western blot analysis of YAP, TAZ, CTGF, and p-YAP in CMT93 or DLD1 cells treated with recombinant periostin for the indicated time (H) or treated with
the indicated concentrations of recombinant periostin for 24 h (I). The experiments were repeated at least twice.
(legend continued on next page)
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Furthermore, the forced decrease in YAP/TAZ expression in tu-
mor cells markedly reduced tumor cell proliferation to a very
low level, even in the presence of periostin stimulation (Figures
4L, S5F, and S5G). These results suggest that periostin pro-
motes tumor cell proliferation and colorectal tumorigenesis
through the activation of YAP/TAZ in a Hippo pathway-depen-
dent manner.
Integrin-FAK-Src Axis Mediates Periostin-Induced YAP/
TAZ Activation in Colorectal Tumor Cells
Next, we investigated the molecular mechanisms by which
periostin induces YAP and TAZ activation in tumor cells. YAP
can be directly phosphorylated and activated by active Src in
intestine epithelial cells and breast cancer cells (Taniguchi
et al., 2015; Sorrentino et al., 2017). The current evidence dem-
onstrates that periostin is one of the ligands and regulators of
integrin/FAK signaling in tumor progression. In tumor microen-
vironments, the enhanced interaction of the ECM proteins,
such as collagens, periostin, tenascin-C, and fibronectin, leads
to integrin-mediated outside-in signaling, including FAK and
Src activation. As an ECM component, periostin is highly ex-
pressed in the colorectal tumors and deposited in the matrix
(Figures 2A–2D). Thus, we proposed that integrin-FAK-Src
signaling may be involved in periostin-induced YAP activation
in colorectal tumorigenesis. To test this hypothesis, we exam-
ined the protein levels of these signaling cascades in two
different tumor cell lines by treatment with mouse or human re-
combinant periostin protein. We found that recombinant peri-
ostin treatment significantly elevated the levels of FAK and
Src phosphorylation, as well as YAP, TAZ, and connective tis-
sue growth factor (CTGF) in CMT93 and DLD1 tumor cells,
which were significantly blocked by adding integrin inhibitory
RGD peptide (Figures 5A–5C). We also found that periostin
strongly enhanced AKT phosphorylation in the two different tu-
mor cell lines (Figure 5A), which was in line with our previous
work (Bao et al., 2004). As an ECM component, periostin usu-
ally binds to integrins such as avb1, avb3, avb5, or a6b4 to
perform its biological functions. Among these integrins, avb3
and avb5 are primarily expressed on tumor cells. Similar to
RGD peptide, avb3 or avb5 neutralizing antibody treatment
increased the level of YAP phosphorylation but markedly
reversed the elevated levels of FAK and Src phosphorylation,
as well as YAP, TAZ, and their target genes induced by perios-
tin in tumor cells through disrupting integrin-mediated outside-
in signaling (Figure 5D). We further confirmed that inhibition of
FAK or Src kinase, but not inhibition of Akt, led to the increased
level of YAP phosphorylation and significantly decreased the
levels of YAP/TAZ and their target gene expression, indicating
the important contributions of FAK and Src to the periostin-(J) Relative mRNA levels of the indicated genes in CMT93 cells transfected with
rmPeriostin for 24 h (n = 3 biological replicates). siCtrl is control siRNA; YAP/TA
composed of oligos YAP 2# and TAZ 2#.
(K) Quantification of YAP/TAZ nuclear localization in CMT93 cells transfected with
medium containing rmPeriostin (n = 3 biological replicates). LATS1/2 siRNA A is c
oligos LATS1 2# and LATS2 2#.
(L) Quantification of Ki67+ and BrdU+ cells in CMT93 cells treated as in (J); n = 3
Each value represents mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
800 Cell Reports 30, 793–806, January 21, 2020induced YAP and TAZ increase (Figure 5E). Our further results
showed that the inhibition of FAK or Src kinase, rather than the
inhibition of Akt, greatly decreased periostin-induced YAP/TAZ
nuclear accumulation (Figures 5F and S6A). To further assess
whether the FAK-Src axis was involved in periostin-enhanced
colorectal tumorigenesis in vivo, we performed western blotting
and immunohistochemical assays and found that the levels of
phosphorylated FAK and Src in the tumors of Postn/ mice
were significantly reduced compared with the tumors from
WT mice (Figures 5G and 5H), suggesting that the FAK-Src
axis is responsible for periostin-enhanced colorectal tumori-
genesis. We also found that the inhibition of Src kinase activa-
tion strongly prevented periostin-induced YAP/TAZ nuclear
localization, but this was significantly reversed by knocking
down LATS1/2 in tumor cells (Figures 5I and S6B). Further-
more, we found that treating YAP-WT transiently transfected
cells with dasatinib significantly prevented periostin-induced
cell proliferation, while YAP-5SA (a mutant form of YAP) trans-
fected cells were almost completely insensitive to the inhibitory
effect of dasatinib on periostin-induced cell proliferation, as evi-
denced by the higher increased proliferative cells (Figures 5J,
5K, and S6C–S6E). These data indicate that the integrin-FAK-
Src axis mediates periostin-induced YAP/TAZ activation and
tumor cell proliferation.
Periostin-Dependent YAP Activation Induces IL-6
Secretion in Tumor Cells to Stimulate Periostin
Expression in Colon Myofibroblasts
After having demonstrated that fibroblast-derived periostin en-
hances YAP/TAZ activation in colorectal tumor cells, we
further determined which cytokine(s) from tumor cells in turn
induced fibroblast activation and, subsequently, periostin
expression. It has been reported that YAP/TAZ activation leads
to the expression of pro-inflammation genes such as Il6, Il8,
and Il1b (Wang et al., 2016a). Another recent report indicates
that IL-6 is a target of YAP and plays a key role in maintaining
the stemness of breast cancer cells (Kim et al., 2015). Consis-
tent with these findings, we found that YAP knockdown was
sufficient to downregulate Il6, but not Il1b or Tnfa expression,
in colorectal tumor cells (Figure S7A). Decreased YAP expres-
sion significantly reversed periostin-induced Il6 production
(Figure 6A), indicating that periostin induces Il6 expression in
tumor cells via YAP activation. Previous reports have revealed
that IL-6 treatment increases collagen expression in fibroblasts
(Duncan and Berman, 1991); thus, we proposed that tumor
cell-derived IL-6 may contribute to fibroblast activation and
periostin expression. To test this hypothesis, we analyzed
the changes in periostin production in the isolated primary co-
lon myofibroblasts treated with recombinant IL-6 protein.indicated small interfering RNAs (siRNAs) for 48 h and treated with or without
Z siRNA A is composed of oligos YAP 1# and TAZ 1#; YAP/TAZ siRNA B is
indicated siRNAs for 48 h and treated with or without RGD for 6 h in serum-free
omposed of oligos LATS1 1# and LATS2 1#; LATS1/2 siRNA B is composed of
biological replicates.
0.0001. Student’s t test. See also Figure S5.
Figure 5. Integrin-FAK-Src Signaling Mediates Periostin-Induced YAP/TAZ Activation in Tumor Cells
(A) Western blot analysis of the indicated proteins in CMT93 and DLD1 cells treated with recombinant periostin alone or in combination with RGD for 6 h in serum-
free medium.
(B andC) Immunofluorescence staining of YAP/TAZ (B) and quantification of nuclear YAP/TAZ (C) in CMT93 cells treated as in (A); n = 4 biological replicates. Scale
bars, 25 mm. Each point represents one macroscopic field.
(D) Western blot analysis of the indicated proteins in CMT93 cells treated with rmPeriostin in the presence or absence of avb3 or avb5 integrin neutralizing
antibody.
(E) Western blot analysis of the indicated proteins in CMT93 cells treated with rmPeriostin alone or together with the indicated inhibitors for 24 h.
(F) Quantification of YAP/TAZ nuclear localization in CMT93 cells treated as in (E) by immunofluorescence (n = 3 biological replicates).
(G) Western blot analysis of p-FAK, FAK, p-Src, and Src in colorectal tumor tissue lysates of AOM/DSS-treated WT (n = 3) and Postn/ (n = 3) mice.
(legend continued on next page)
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Accompanying the activation of colon myofibroblasts, the
abundance of Postn mRNA was significantly increased in a
time- and dose-dependent manner by IL-6 stimulation (Figures
6B and 6C). Moreover, STAT3-signaling inhibitor Stattic treat-
ment significantly reduced the increase in the mRNA and pro-
tein levels of periostin induced by IL-6 (Figures 6D and S7B),
suggesting that IL-6-STAT3 signaling is responsible for perios-
tin expression in activated fibroblasts. To further determine
whether IL-6-STAT3 signaling was associated with fibroblast
activation and periostin increase during CAC progression, we
analyzed the expression of Il6, Acta2, and Postn during the
course of AOM/DSS colitis. We found that the levels of Il6,
Acta2, and Postn were significantly increased during the
development of AOM/DSS-induced CAC (Figures 6E and
S7C), which were further confirmed by western blot analysis
(Figure 6F). Furthermore, immunohistochemical staining as-
says showed that p-STAT3, a-SMA, and periostin were highly
expressed in stromal cells of the inflamed colonic and
tumorous tissues (Figure 6G). These results demonstrate that
periostin-induced YAP activation results in IL-6 expression in
tumor cells, which in turn stimulates colon myofibroblast
activation and periostin expression. Therefore, we conclude
that under the pathological conditions of inflammation and/or
tumor, elevated IL-6 can stimulate colon myofibroblast
activation and periostin expression to facilitate colorectal
tumorigenesis.
Periostin Is Highly Expressed in Patients with Intestinal
Diseases and Correlates with YAP/TAZ Expression in
Human Colorectal Tumors
Next, we analyzed periostin expression in human intestinal tis-
sues and tissues from patients with inflammatory bowel dis-
eases (ulcerative colitis and Crohn disease) or colorectal tumors.
We found that the expression of periostin in ulcerative colitis and
Crohn disease samples and tumors was higher than that in
normal tissues (Figures 7A and 7B) and that periostin was depos-
ited in the stromal component (Figure 7A). Notably, YAP/TAZ
was significantly increased in human colorectal tumors (Fig-
ure 7B) and was mainly localized in tumor cells (Figure 7A). We
also detected a weak increase in YAP/TAZ in inflammatory dis-
order samples (Figures 7A and 7B). In contrast, the level of
YAP phosphorylation was strongly reduced in human tumors
(Figure 7B). The analysis of the tissuemicroarray further revealed
significant increases in periostin and YAP/TAZ expression in
colorectal tumors compared with adjacent non-tumorous tis-
sues (Figures 7C and 7D). Moreover, we found a stronger posi-
tive correlation between periostin and YAP/TAZ expression in
colorectal tumors (Figure 7E). These data suggest that periostin
positively correlates with inflammatory intestinal disease devel-
opment and especially with YAP/TAZ expression in human colo-
rectal tumors.(H) Immunohistochemical staining of p-Src in the tumors from WT and Postn/
(I) Quantification of nuclear YAP/TAZ in CMT93 cells transfected with the indicat
dasatinib for 24 h (n = 3 biological replicates).
(J and K) Quantification of Ki67+ (J) and BrdU+ (K) cells in CMT93 cells transfect
together with dasatinib for 24 h (n = 3 biological replicates).
Each value represents mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
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Accumulating evidence shows that periostin plays important
roles in mediating inflammatory responses and tumor progres-
sion. Our previous study demonstrates that periostin can pro-
mote liver metastasis of CRC (Bao et al., 2004). However, the
roles of periostin in CAC development remain controversial (Shi-
moyama et al., 2018; Koh et al., 2019), and the underlyingmolec-
ular mechanisms are still largely unknown. Here, we applied an
AOM/DSS-induced inflammation-associated CRC model and
an ApcMin/+ spontaneous intestinal tumor model to investigate
the role of periostin in colorectal tumor development. We found
that knockout of periostin exhibits a tumor-inhibiting role, not
only in the CAC mouse model but also in the ApcMin/+ mouse in-
testine tumor model. Therefore, our data definitely demonstrate
that periostin deficiency attenuates colorectal tumorigenesis
in mice. Moreover, we found that periostin-knockout mice
exhibit fewer proliferative cells in colorectal tumor tissues
and that periostin treatment promotes colorectal tumor cell pro-
liferation in vitro. These data suggest that periostin has the ca-
pacity for enhancing epithelial cell proliferation during colorectal
tumorigenesis.
The Hippo pathway has been reported to be involved in the
development of intestinal diseases, including inflammatory
bowel diseases and CRC. In DSS-induced mouse colitis tissues,
increased YAP nuclear localization was found in gp130-active in-
testinal epithelial cells (Taniguchi et al., 2015). InMst1/Mst2-defi-
cient intestinal epithelium, YAP is preferential nuclear localization
(Zhou et al., 2011). YAP is overexpressed in human colorectal
tumors, and depletion of YAP can inhibit cell proliferation and
survival (Hong et al., 2016).Moreover, higher YAP or TAZ expres-
sion is positively correlated with poor survival outcomes in
patients with colon cancer (Hong et al., 2016; Wang et al.,
2013; Yuen et al., 2013). Here, we found that periostin deficiency
significantly reduces YAP/TAZ total protein levels and their nu-
clear localization in mouse tumors. Moreover, recombinant peri-
ostin treatment can significantly increase total YAP/TAZ levels
and enhance the nuclear translocation of YAP/TAZ in colorectal
tumor cells. Ctgf, Cyr61, and Ankrd1 are strikingly upregulated
after periostin treatment, and knockdown of YAP/TAZ can
reverse the effect induced by periostin. Knocking down YAP/
TAZ expression in tumor cells significantly suppresses cell pro-
liferation, even in the presence of periostin treatment. Therefore,
our findings indicate that periostin enhances tumor cell prolifer-
ation via regulating YAP/TAZ activation during colorectal
carcinogenesis.
Tumor cells can release many types of soluble factors to
educate stromal cells and remodel tissue microenvironments
to sustain their own survival and growth (Grivennikov et al.,
2010). A recent study demonstrated that IL-6 plays a major
role in mediating dynamic cross-talk between tumor cellsmice. Scale bars, 50 mm.
ed siRNAs for 48 h and treated with rmPeriostin alone or in combination with
ed with the indicated plasmids for 48 h and treated with rmPeriostin alone or
0.0001. Student’s t test. See also Figure S6.
Figure 6. IL-6-STAT3 Signaling Is Involved in Fibroblast Activation and Periostin Expression during CAC Development
(A) Relative mRNA level of Il6 in CMT93 cells transfected with the indicated siRNAs for 48 h and treated with or without rmPeriostin for 24 h (n = 3 biological
replicates).
(B) Relative mRNA levels of Acta2 and Postn in isolated CMFs treated with rmIL-6 for the indicated times (n = 3 biological replicates).
(C) Relative mRNA expression of Acta2 and Postn in CMFs treated with the indicated concentrations of rmIL-6 for 48 h (n = 3 biological replicates).
(D) Western blot analysis of p-STAT3, a-SMA, and periostin in isolated primary CMFs treated with rmIL-6 alone or together with STAT3 inhibitor Stattic for 48 h.
(E) Relative mRNA levels of Il6, Acta2, and Postn in the distal colonic tissue lysates of WT mice (n = 3) during the course of colitis-associated tumor formation.
(F) Western blot analysis of p-STAT3, a-SMA, and periostin in the colonic tissue lysates of WT mice treated as in (E).
(G) H&E staining and immunohistochemical staining of p-STAT3, a-SMA, and periostin in the non-tumorous (days 0–57) and tumorous (day 80) tissues of AOM/
DSS-treated WT mice. Scale bars, 50 mm.
Each value represents mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001; Student’s t test. See also Figure S7.and activated fibroblasts in head and neck squamous cell car-
cinoma, esophageal cancer, and gastric adenocarcinoma by
supporting the growth of tumor cells and promoting the activa-
tion of fibroblasts (Karakasheva et al., 2018). Another report
reveals a key role for the IL-6-STAT3 axis in fibroblast growth
factor 19 (FGF19)-driven hepatocarcinogenesis, while block-
ing this axis in hepatocytes abolishes FGF19-induced tumori-genesis (Zhou et al., 2017). STAT3 can induce periostin
expression by directly binding to its promoter (Amara et al.,
2015). Here, we found that the deletion of periostin signifi-
cantly decreases the level of IL-6 in AOM/DSS-induced mouse
tumor tissues. We also observed that knocking down YAP is
sufficient to downregulate Il6 expression and that periostin-
induced YAP leads to the increase of Il6 in tumor cells.Cell Reports 30, 793–806, January 21, 2020 803
Figure 7. Periostin Is Highly Expressed in Human Intestinal Diseases and Positively Correlates with YAP/TAZ Expression in Human Colo-
rectal Tumors
(A) Representative images of H&E staining and the immunohistochemical staining of periostin and YAP/TAZ in human normal intestine, inflammatory bowel
diseases (ulcerative colitis [UC] and Crohn disease [CD]), and colorectal tumors. Scale bars, 50 mm.
(B) Western blot analysis of periostin, p-YAP, YAP, and TAZ in the tissue lysates of human normal mucosa, inflammatory bowel diseases, and tumors.
(C and D) Analysis of the immunoreactive score (IRS) of periostin (C) and YAP/TAZ (D) expression by immunohistochemistry in colorectal tumorous tissues and the
adjacent non-tumorous tissues. IRS scores of 0–1 were analyzed as negative, 2–3 asmild, 4–8 asmoderate, and 9–12 as strongly positive. Each point represents
the IRS score of periostin (C) or YAP/TAZ (D) in one individual tissue section. Data are means ± SEMs (n = 49); **p < 0.01, ****p < 0.0001; Student’s t test.
(E) Correlation analysis of periostin and YAP/TAZ expression in human colorectal tumors.Moreover, recombinant IL-6 protein can increase periostin
expression in isolated colon myofibroblasts via STAT3 activa-
tion. Therefore, IL-6-STAT3 signaling is responsible for perios-
tin expression in activated fibroblasts during colorectal
tumorigenesis.
Immune and/or inflammatory cells can produce tumor-pro-
moting cytokines to remodel the initial hostile tissue microen-
vironment, which may occur in the early or late stages of
tumor development (Grivennikov et al., 2010). In this study,
we found that Postn/ mice have a significant reduction in
inflammation such as less infiltrated inflammatory cells and
reduced chemokines during the first cycle of AOM/DSS treat-
ment. We further demonstrated that the significantly increased
level of periostin is deposited in the stromal component and
that the absence of periostin prevents precancerous lesion
formation in the inflamed colon tissue. Our findings suggest
that the released inflammatory mediators by infiltrated im-
mune cells may also be involved in inducing the secretion of
periostin and thereby facilitate the precancerous lesion forma-
tion during the early phase of CAC progression. Therefore, it is
worthwhile to further characterize how stromal periostin facil-
itates tumor onset and outgrowth by recruiting inflammatory
immune cells in tissues.804 Cell Reports 30, 793–806, January 21, 2020In conclusion, we demonstrate that CAF-derived periostin
enhances the activation of YAP via the integrin-FAK-Src
pathway, thereby increasing the expression of IL-6 in tumor
cells, which in turn stimulates fibroblasts to produce periostin
via STAT3 activation. Our study provides strong evidence to sup-
port the hypothesis that the periostin-IL-6 loop contributesto
regulating the interaction between tumor cells and fibroblasts
during colorectal tumorigenesis. Targeting periostin- and IL-6-
mediated tumor-stroma interaction may be an attractive thera-
peutic strategy for human colorectal tumors.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-Periostin Adipogen Cat# AG-20B-0033; RRID: AB_2490231
Rabbit monoclonal anti-Phospho-STAT3 Cell Signaling Technology Cat# 9145; RRID: AB_2491009
Mouse monoclonal anti-STAT3 Cell Signaling Technology Cat# 9139; RRID: AB_331757
Rabbit monoclonal anti-Phospho-AKT Cell Signaling Technology Cat# 4060; RRID: AB_2315049
Rabbit monoclonal anti-AKT Cell Signaling Technology Cat# 4691; RRID: AB_915783
Rabbit polyclonal anti-Phospho-FAK Cell Signaling Technology Cat# 3283; RRID: AB_2173659
Rabbit monoclonal anti-FAK Abcam Cat# ab40794; RRID: AB_732300
Rabbit monoclonal anti-Phospho-ERK1/2 Cell Signaling Technology Cat# 9101; RRID: AB_331646
Rabbit monoclonal anti-ERK1/2 Cell Signaling Technology Cat# 9102; RRID: AB_330744
Rabbit monoclonal anti-b-actin Cell Signaling Technology Cat# 8457; RRID: AB_10950489
Anti-Integrin aVb3 antibody Millipore/Merck Cat# MAB1876; RRID: AB_569486
Anti-Integrin aVb5 antibody Millipore/Merck Cat# MAB1961Z; RRID: AB_94466
Rabbit monoclonal anti-Ki67 Cell Signaling Technology Cat# 12202; RRID: AB_2620142
Rabbit monoclonal anti-b-Catenin Cell Signaling Technology Cat# 8480; RRID: AB_11127855
Rabbit monoclonal anti-iNOS Cell Signaling Technology Cat# 13120; RRID: AB_2687529
Rabbit monoclonal anti-Cyclin D1 Cell Signaling Technology Cat# 2978; RRID: AB_2259616
Rabbit monoclonal anti-c-Myc Abcam Cat# ab32072; RRID: AB_731658
Rabbit monoclonal anti-Phospho-Src Cell Signaling Technology Cat# 2101; RRID: AB_331697
Rabbit monoclonal anti-Src Cell Signaling Technology Cat# 2109; RRID: AB_2106059
Rabbit monoclonal anti-YAP Cell Signaling Technology Cat# 14074; RRID: AB_2650491
Rabbit monoclonal anti-Phospho-YAP Cell Signaling Technology Cat# 13008; RRID: AB_2650553
Rabbit polyclonal anti-CTGF Abcam Cat# ab6992; RRID: AB_305688
Rabbit monoclonal anti-Phospho-LATS1 Cell Signaling Technology Cat# 8654; RRID: AB_10971635
Rabbit polyclonal anti-LATS1 Abcam Cat# ab70561; RRID: AB_1209494
Rabbit polyclonal anti-TAZ Abcam Cat# ab84927; RRID: AB_1925489
Rabbit monoclonal anti-YAP/TAZ Cell Signaling Technology Cat# 8418; RRID: AB_10950494
Rabbit monoclonal anti-GAPDH Cell Signaling Technology Cat# 5174; RRID: AB_10622025
Rabbit polyclonal anti-aSMA Abcam Cat# ab52218; RRID: AB_870573
Rabbit polyclonal anti-LATS2 Abcam Cat# ab174499; RRID: N/A
Rabbit polyclonal anti-ANKRD1 BBI Life Science Cat# D121628; RRID: N/A
Rabbit polyclonal anti-CYR61 BBI Life Science Cat# D222190; RRID: N/A
Rat monoclonal anti-F4/80 Abcam Cat# ab16911; RRID: AB_443548
Rat monoclonal anti-Ly6g Abcam Cat# ab25377; RRID: AB_470492
Rabbit polyclonal anti-CD45 Abcam Cat# 208002; RRID: N/A
Mouse monoclonal anti-BrdU Cell Signaling Technology Cat# 5292; RRID: AB_10548898
Rabbit monoclonal anti-Vimentin Cell Signaling Technology Cat# 5741; RRID: AB_10695459
Rabbit polyclonal anti-EpCAM Abcam Cat# ab71916; RRID: AB_1603782
Biological Samples
Human inflammatory bowel disease and tumor
samples
Shanghai General Hospital of
Shanghai Jiao Tong University
N/A
Tissue arrays (Col015-118e) Alenabio http://alenabio.bioon.com.cn/
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Chemicals, Peptides, and Recombinant Proteins
Lipofectamine RNAi-MAX Reagent Invitrogen Cat# 13778030
STAT3 inhibitor Stattic Selleck Chemicals Cat# S7024
Src inhibitor PP2 Selleck Chemicals Cat# S7008
Src inhibitor dasatinib Selleck Chemicals Cat# S1021
AKT inhibitor LY294002 Selleck Chemicals Cat# S1105
RGD peptide PEPTIDES Cat# PCI-3661-PI
Recombinant Human Periostin/OSF-2 Protein R&D Systems Cat# 3548-F2-050
Recombinant Mouse Periostin/OSF-2 Protein R&D Systems Cat# 2955-F2-050
Recombinant Mouse IL-6 Protein R&D Systems Cat# 406-ML-025
Azoxymethane (AOM) Sigma-Aldrich Cat# A5486
Dextran sulfate sodium salt (DSS) MP Biomedicals Cat# 160110
Lipofectamine 3000 Transfection Reagent Invitrogen Cat# L3000001
FAK inhibitor PF573228 Selleck Chemicals Cat# S2013
Critical Commercial Assays
Mouse IL-6 ELISA Kit R&D Systems Cat# DY406
Mouse TNFa ELISA Kit R&D Systems Cat# DY410
Mouse IL-1b ELISA Kit R&D Systems Cat# DY401
Experimental Models: Cell Lines
Mouse: CMT93 ATCC CCL-223
Human: DLD1 ATCC CCL-221
Mouse: CMF (colon myofibroblast) This paper N/A
Mouse: CAF (cancer-associated fibroblast) This paper N/A
Experimental Models: Organisms/Strains
Mouse: B6.129-Postntm1Jmol/J Jackson Laboratory JAX: 009067
Mouse: C57BL/6 Nanjing Biomedical Research
Institute of Nanjing University
N000013
Mouse: C57BL/6J-ApcMin/J Jackson Laboratory JAX: 002020
Oligonucleotides
siRNA targeting sequence: siYAP
1# GCAUGAGCAGCUACAGCAUTT
This paper N/A
siRNA targeting sequence: siYAP
2# GCUGAUGAAUUCUGCCUCATT
This paper N/A
siRNA targeting sequence: siYAP
3# GAUCCCUGAUGAUGUACCATT
This paper N/A
siRNA targeting sequence: siTAZ
1# GGAUUAGGAUGCGUCAAGATT
Calvo et al., 2013 N/A
siRNA targeting sequence: siLATS1
1# GCAAGUCACUCUGCUAAUUTT
This paper N/A
siRNA targeting sequence: siLATS1
2# GGUGAAGUCUGUCUAGCATT
This paper N/A
siRNA targeting sequence: siLATS2
1# GCCACAACUUACUCUGGAATT
This paper N/A
siRNA targeting sequence: siLATS2
2# GCCUCAAUGCUGACUUGUATT
This paper N/A
siRNA targeting sequence: siTAZ
2# CGAGAUGGAUACAGGUGAATT
Calvo et al., 2013 N/A
See Table S1 for qRT-PCR primer sequences This paper N/A
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Recombinant DNA
Plasmid: pCMV5-Flag-YAP wild-type Liu et al., 2018 N/A
Plasmid: pCMV5-Flag-YAP 5SA Liu et al., 2018 N/A
Software and Algorithms
GraphPad Prism 5 GraphPad Software https://www.graphpad.com/
Bio-Rad CFX Manager 3.0 CFX Manager Software http://www.advanceduninstaller.comLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gaoliang
Ouyang (oygldz@xmu.edu.cn).
All unique and stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Studies
We maintained all animals under specific pathogen-free conditions at the Laboratory Animal Center of Xiamen University. All animal
experiments were performed in accordance with the animal study protocols approved by the Animal Care and Use Committee of
Xiamen University. C57BL/6 mice were originally obtained from Nanjing Biomedical Research Institute of Nanjing University and
were maintained in the Laboratory Animal Center of Xiamen University. Postn+/ and ApcMin/+ mice were originally purchased
from the Jackson Laboratory. Wild-type and periostin-deficient mice were generated by crossing Postn+/ mice with Postn+/
mice as described previously (Ma et al., 2019). For the generation of Postn/ApcMin/+mice, ApcMin/+mice in a C57BL/6 background
were crossed with Postn+/ mice in a C57BL/6 background. Age- and sex-matched Postn/ApcMin/+ mice and Postn+/+ApcMin/+
mice were analyzed for intestine tumor formation at 6-month-old. Minimum of 3 mice per group were used in this research. Mouse
with dermatitis, urethritis or fight wounds was excluded from the experimental analysis.
Colitis-associated colorectal tumor formation was induced inmice as previously described (Karki et al., 2016; Huber et al., 2012). In
brief, 6- to 8-week-oldmalewild-type andPostn/micewere injected intraperitoneally withmutagen AOM (Sigma-Aldrich) at a dose
of 10 mg/kg body weight. Five days after AOM injection, mice were subjected to 3 cycles of 3% DSS (MP Biomedicals, molecular
mass 36,000-50,000) in drinking water for 5 days followed by regular drinking water for 16 days. Mice were sacrificed on day 80
of the experimental protocol. The colons were collected from themice and placed on the ice-cold PBSwetted gauze. After the colons
were cut open longitudinally and cleaned with ice-cold PBS, the distal colon tissues were kept in different conditions depending on
the subsequent experimental requirements. For enzyme-linked immunosorbent assay (ELISA) measurements of inflammatory cyto-
kines, fresh colon tissues were homogenized, snap frozen and thawed on ice, then cleared by centrifugation at 4C and the super-
natants were used for test. Samples for western blotting or RNA isolation, distal colons were snap-frozen in liquid nitrogen for 10 min
and then stored at 80C. For tumor sample collection, AOM/DSS-induced colon tumors or tumors in the small and large intestines
of 6-month-old ApcMin/+ mice were counted and the size of each tumor was measured in each mouse. Some intestine tumors either
from AOM/DSS-induced mice or from ApcMin/+ mice were placed on 4% PFA wetted gauze for 30 min to be fixed, then dehydrated
and Paraffin-embedded for further immunohistochemical assay.
Human Tissue Samples
The collection and study of human tissue samples was performed in accordance with the approved guidelines of the Ethics and Sci-
entific Committees of Shanghai Jiao Tong University. Clinical samples were collected from colorectal carcinoma patients (n = 7), ul-
cerative colitis patients (n = 5) and Crohn’s disease patients (n = 5) who underwent surgical resection or colonoscopy in Shanghai
General Hospital. All of these obtained specimens were from previously untreated patients and both the male and female patients
were included. After excision, specimens were fixed in 4% formalin or stored at80C for further studies. 5 paired tumor and relative
normal mucosa samples, 3 ulcerative colitis samples and 3 Crohn’s disease specimens were available for performing western blot-
ting assay. 2 paired tumor and normal mucosa samples, 2 ulcerative colitis samples and 2 Crohn’s disease samples were available
for performing immunohistochemical study. Tissue arrays (Col015-118e) were purchased from Alenabio.
Cell Culture
CMT93 and DLD1 cell lines were purchased from American Type Culture Collection (ATCC). CMT93 cells were cultured in DMEM
(GIBCO) supplemented with 10% FBS (HyClone) and 1% penicillin and streptomycin (GIBCO); DLD1 cells were cultured in RPMI
1640 medium (GIBCO) with 10% FBS and 1% penicillin and streptomycin. All cell lines were maintained at 37C with 5% CO2 inCell Reports 30, 793–806.e1–e6, January 21, 2020 e3
a humidified atmosphere. All cell lines were regularly tested formycoplasma contamination by PCR-basedmethod andwere found to
be negative.
Primary Colon Myofibroblast and CAF Isolation
Primary colon myofibroblasts (CMFs) were isolated as reported previously (Khalil et al., 2013). In brief, 4- to 5-week-old wild-type
mouse colon was removed and linearized, cleared of feces by flushing with ice-cold PBS. The colon was incubated in HBSS sup-
plementing with 5 mM EDTA for 15 minutes at room temperature with shacking to remove the normal epithelial cells. After twice
washing, colon tissue was digested for 1.5 hours at 37C in the following solution: 20 mL of RPMI-5 containing 10.5 mg of Dispase
(Roche) and 7.2 mg of collagenase D (Sigma). Centrifugation and resuspending the pellet with 10 mL RPMI-5 medium and passing
through 70 mm mesh strainer into a 100 mm dish. After 3 hours, the nonadherent cells were washed off with PBS and cells were
cultured in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. All primary colon myofibroblasts were used
before reaching the third passage.
For CAF isolation (Kesselring et al., 2016), tumors were obtained from tumor burden colons of AOM/DSS-treated wild-type and
Postn/mice. Tumor tissues were incubated in the EDTA chelation buffer for 1 hour on ice to remove normal epithelia cells. Tumor
fragments were digested in the following buffer for 2 hours at 37C: DMEM medium containing 2.5% FBS, 1% penicillin and strep-
tomycin, 125mg/ml dispase II, 200 U/ml collagenase IV and amphotericin B (Invitrogen). The supernatant was collected and followed
by passing through 70 mm mesh strainer into a 6 cm dish. After 2-3 hours, the nonadherent cells were washed off and new medium
was changed. When reaching 75%–90% confluence, the cells were washed twice with PBS and continued to be cultured in serum-
free medium for 1 hour. After twice washing again, cells were cultured in the serum-free medium for 48 hours and conditioned media
were collected.
METHOD DETAILS
Determination of Disease Activity Index
Disease activity index was assessed as described previously in detail (Hartmann et al., 2000; Siegmund et al., 2001). Body weights,
stool consistency and occult blood were monitored daily or weekly according to the protocol. For body weight loss analysis, no body
weight loss was analyzed as 0 score, increased body weight loss between 1 and 5%as 1 score, 5 to 10% as 2 scores, 10 to 20% as 3
scores, and a score of 4 was analyzed as more than 20% body weight loss. For the stool consistency, well-formed pellets were
analyzed as 0 score, pasty and semi-formed stools that did not adhere to the anus were analyzed as 2 scores, and a score of 4
was analyzed for liquid stools that remained adhered to the anus. For occult blood measurement, no blood in hemoccult was
analyzed as 0 score, positive hemoccult was analyzed as 2 scores, and a score of 4 was analyzed as gross bleeding from the rectum.
All these scores were added and divided by 3 to obtain a total disease activity index ranging from 0 to 4 in one individual mouse.
Histological Score and Tumors Analysis
After cervical dislocation, the entire colon was removed from the cecum to the anus and placed on gauze wetted with ice-cold PBS,
the colon was opened longitudinally and cleared of feces by flushing with ice-cold PBS, followed by division into thirds from the prox-
imal, middle and distal colon, then placed on gauze wetted with 4% PFA for 30 minutes at room temperature. After performing the
‘‘petit four’’ arrangement composed of tissues and agar and fixed overnight at 4C in 4% PFA (Zhang et al., 2015), the colon tissues
were embedded in paraffin for histological analysis. Colonic tissue sections (5 mm) were performed by H&E staining, and histologic
scoring was analyzed according to the protocol described previously (Kesselring et al., 2016). Tumor load was analyzed according to
the formula: tumor load = (number of small tumors) 3 1 + (number of medium tumors) 3 2 + (number of large tumors) 3 3.
Bone Marrow Chimeric Mice Generation
BM chimeric mice were generated to determine the cellular basis contribution to the development of colorectal tumorigenesis. BM
from donor wild-type and Postn/mice was prepared from femurs and tibias. Twomonth-old recipient wild-type and Postn/mice
were irradiated with a single lethal dose (9 Gry), and 2 3 107 BM cells from donor mice were intravenously injected 4 hours later.
We performed 4 groups of BM chimeric mice as following: wild-type BM to Postn/, Postn/ BM to wild-type, Postn/ BM to
Postn/, andwild-type BM towild-typemice. Four weeks after BM transplantation, efficiency of BM transplantation was determined
as described previously (Popivanova et al., 2008). After 2 months, BM chimeric mice were subjected to AOM/DSS to induce colo-
rectal tumor formation and sacrificed on day 80.
Western Blot Analysis
For immunoblotting, total proteins were extracted from colon tissue or cells using RIPA lysis buffer supplemented with protease and
phosphatase inhibitors (Roche) as previously reported (Karki et al., 2016). Samples were separated on 8%–10%SDS-PAGE gels and
transferred onto PVDFmembranes (Millipore). Membranes were blocked in 5%BSA for at least 1 hour at room temperature and then
incubated in primary antibodies overnight at 4C. After washing with TBST for 30 minutes, the membranes were incubated with
HRP-conjugated secondary antibody for 1 hour at room temperature. After washing again, proteins were visualized on X-ray films.
The primary antibodies to b-actin, p-AKT, AKT, b-Catenin, Cyclin D1, p-ERK1/2, ERK1/2, p-FAK, GAPDH, iNOS, p-LATS1, p-Src,e4 Cell Reports 30, 793–806.e1–e6, January 21, 2020
Src, p-STAT3, STAT3, YAP, p-YAP and YAP/TAZ were purchased from Cell Signaling Technology. Anti-periostin antibody was
obtained from Adipogen. Anti-c-Myc, anti-CTGF, anti-LATS1, anti-TAZ, anti-FAK, anti-a-SMA and anti-LATS2 antibodies were ob-
tained from Abcam. Anti-ANKRD1and anti-CYR61 antibodies were purchased from BBI Life Science.
Immunohistochemical Staining
For immunohistochemistry analysis, colonic tissue sections were placed at 65C for 1 hour and then deparaffinized in xylene and
alcohol. Antigen retrieval was performed in 0.01 M sodium citrate buffer at 98C for 10 minutes. Slides were blocked with normal
goat serum, followed by incubating overnight at 4C with the primary antibodies as the following: anti-Ki67 (Cell Signaling,
#12202, 1:200), anti-F4/80 (Abcam, #ab16911, 1:200), anti-Gr-1 (Abcam, #ab25377, 1:200), anti-CD45 (Abcam, #208002, 1:200),
anti-YAP/TAZ (Cell Signaling, #8418, 1:200), anti-p-Src (Abcam, #ab40660, 1:200), anti-periostin (Adipogen, #AG-20B-0033,
1:200), anti-BrdU (Cell Signaling, #5292, 1:500), anti-p-STAT3 (Cell Signaling, #9145, 1:200) and anti-a-SMA (Abcam, #ab52218,
1:400). After washing for 30 minutes, slides were incubated with anti-mouse or rabbit secondary antibody for 45 minutes at room
temperature. After washing for 30 minutes, slides were stained with streptavidin-horseradish peroxidase conjugates and incubated
for 20 minutes. The colonic tissue sections were washed 4 times, followed by staining with DAB, and then counterstained with he-
matoxylin. The number of Ki67- or BrdU-positive cells per crypt in one individual mouse was counted for at least 9 crypts per mouse,
and at least 3 mice per experimental group were analyzed.
Immunofluorescent Staining
For immunofluorescent staining of colon tumor sections, tissues were dehydrated in increasing concentrations of sucrose, and
embedded in OCT followed by placing at 80C for sectioning. 8 mm thickness tissue sections were baked at 55C for 30 minutes
and then fixed with ice-cold acetone for 10 minutes at20C. After washing with PBS for three times, slides were incubated with 3%
BSA solution and then incubated overnight at 4Cwith the primary antibodies: anti-periostin (Adipogen, #AG-20B-0033, 1:200), anti-
F4/80 (Abcam, #ab16911, 1:200), anti-a-SMA (Abcam, #ab52218, 1:300), anti-Vimentin (Cell Signaling, #5741, 1:200), anti-EpCAM
(Abcam, #ab71916, 1:200). For 30 minutes washing, slides were incubated with secondary antibodies for 1 hour, followed by coun-
terstaining with Hoechst. Images were taken with a Zeiss LSM 780 confocal microscope.
For cell immunofluorescent staining, CMT93 cells were seeded on 20- or 25-mmdiameter glass slides placed in 12- or 6-well plate.
After serum starvation overnight or transfection, cells were treated with mouse recombinant periostin protein or conditioned medium
for 24 hours. 2 mMBrdU was added into cell culture medium 3 hours before cells fixed. Cells were fixed with 4% PFA for 30 minutes,
then slides were washed and permeabilized, followed by blocking with 10% FBS for 1 hour and then incubated with the following
antibodies overnight at 4C: anti-Ki67 (Cell Signaling, #12202, 1:200), anti-BrdU (Cell Signaling, #5292, 1:500), anti-YAP/TAZ (Cell
Signaling, #8418, 1:200). Slides were washed with PBS for 30 minutes and then secondary antibodies were incubated for 1 hour
at room temperature. Hoechst was dyed for visualizing cell nuclei. Images were taken with a Zeiss LSM 780 confocal microscope.
Real-Time Polymerase Chain Reaction
RNAs were extracted from colon tissue or cells using Trizol (Invitrogen) and complemental DNA were generated using ReverTra Ace
qPCR RT kit (FSQ-101, TOYOBO) according to the manufacturer’s instructions. Real-time PCR was performed using the 23 Trans-
Start Top Green qPCR SuperMix (Transgene). Primer sequences were listed in the Table S1. The PCR results were normalized to
Gapdh expression.
Enzyme-Linked Immunosorbent Assay for Cytokines
Cytokines in the colon tissue were analyzed by mouse IL-6 ELISA kit (R&D Systems), TNFa ELISA kit (R&D Systems) and IL-1b ELISA
kit (R&D Systems) according to the manufacturer’s instructions, respectively.
Transfection and Reagents
Cells were cultured in standard conditions and siRNA transfection was performed with Lipofectamine RNAi-MAX (Invitrogen) in
serum- and antibiotics-free medium according to the manufacturer instructions. When reaching 60% confluence, cells were sub-
jected to 100 nM final concentration of siRNAs. siRNAs were purchased from Sangon Biotech (Shanghai, China), and the sequences
of the siRNAs were listed in Key Resources Table. pCMV5-Flag-YAP wild-type and pCMV5-Flag-YAP 5SA plasmids were used as
described previously (Liu et al., 2018).
The following reagents and inhibitors were applied: recombinant mouse periostin protein (#2955-F2-050, R&D Systems); recom-
binant human periostin protein (#3548-F2-050, R&D Systems); recombinant mouse IL-6 protein (#406-ML-025/CF, R&D Systems);
Stattic, 2.5 mM (#S7024, Selleck); PP2, 10 mM (#S7008, Selleck); dasatinib, 0.3 mM (#S1021, Selleck); PF573228, 10 mM (#S2013,
Selleck); LY294002, 10 mM (#S1105, Selleck); RGD, 0.5mg/ml (Selleck); avb3 or avb5 blocking antibody, 0.1 mg/ml (Merck Millipore).
QUANTIFICATION AND STATISTICAL ANALYSIS
GraphPad Prism 5.0 software was used for all experimental result analysis. All data were represented as the mean ± standard error
of the mean (SEM). All n-values per group are reported in the figure legends. Statistical significance is represented in figures asCell Reports 30, 793–806.e1–e6, January 21, 2020 e5
follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 and n.s. indicates not significant. Statistical significance was analyzed by
the Student’s two-tailed t test for two groups or analysis of variance (ANOVA) analysis for more groups. A p value that was less than
0.05 was considered statistically significant. For each quantification by immunofluorescence, at least 6 macroscopic fields per bio-
logical replicates and at least 3 biological replicates per group were analyzed. In the study, no statistical methods were used to pre-
determine sample size, and the investigators were not blinded to allocation during experiments and result analysis.
DATA AND CODE AVAILABILITY
This study did not generate new datasets or code.e6 Cell Reports 30, 793–806.e1–e6, January 21, 2020
